#1CYTEK TRANSCEND THE CONVENTIONAL Advancing the Next Generation of Cell Analysis September 2021#2Disclaimer This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the size and growth of the cell analysis market; Cytek's anticipated total addressable market; Cytek's business and operational strategy; Cytek's prospective products; Cytek's business development plans and opportunities; Cytek's anticipated customer mix and collaborations plans; and objectives of management for future operations are forward looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, including, without limitation, statements The words "may," "will," "expect," "anticipate," "aim,” “estimate,” “intend," "plan," "believe," "is/are likely to," "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to market conditions; the ongoing COVID-19 pandemic; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization; Cytek's ability to maintain, protect and enhance its intellectual property; and Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cytek's own internal estimates and research. While Cytek believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from publicly available information, management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. Cytek, cFluor, Full Spectrum Profiling, FSP, Northern Lights, Similarity and Complexity are trademarks or registered trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders. CYTEK TRANSCEND THE CONVENTIONAL N#31. Cytek is Becoming the Premier Cell Analysis Company |||||| like some 8 8+8 Novel, patented FSP platform utilizes the full spectrum of fluorescent signatures to deliver high-resolution, high-content and high-sensitivity cell analysis Highly intuitive, integrated workflow solutions driving strong adoption with over 850 instruments placed since commercial launch in 2017 Validated platform with over 270 peer-reviewed publications, which continues to accelerate alongside growing applications Delivering strong revenue growth of 59% YoY for the second quarter of 2021 Potential utility across a myriad of research and clinical applications could allow Cytek to access the broader $23Bn cell analysis market¹ Comprehensive suite of solutions expands customer base and diversification, and provides recurring revenue opportunity 2024 market projection estimate CYTEK TRANSCEND THE CONVENTIONAL#4Cytek's Leadership Team Wenbin Jiang, Ph.D. Chief Executive Officer LIGHTSPEED BANDWIDTH> LUMENTUM Valerie Barnett General Counsel Dermira FLUIDIGM WILSON SONSINI Ray Lannigan VP, Global Sales & Service BD Patrik Jeanmonod Chief Financial Officer CORE COVANCE BRAND S Mark Edinger VP, Scientific Affairs OBDQ²Solutions Ken Riley General Manager Ming Yan, Ph.D. Chief Technology Officer BD NEOPhotonics BD INTUITIVE SURGICAL Allen Poirson, Ph.D. SVP, Marketing and Corporate Development SONY Acculmage two AR Biotechnology Maria Jaimes, M.D. VP, Applications BD Melik Ulusu VP, Operations & Integrated Supply Chain BD PerkinElmer CYTEK TRANSCEND THE CONVENTIONAL#5Investing to Capture the Cell Analysis Opportunity Broad Customer Base and Global Presence Validated Technology Platform 850+ Units Placed 270+ Publications 620+ Customers 25+ Countries Strong Financial Profile $93M 2020 Revenue $30.4M 2Q21 Revenue Aurora Northern Lights Reagents Cell Sorter CEVTER CYTEK TRANSCEND THE CONVENTIONAL 2017 2018 2020 2021 5#6To better understand our immune system, with its large and complex network of different cells and their sub-populations, there has been a growing need for higher complexity cell analysis experiments and assays to analyze MORE cell populations together in a single tube of sample FOR MORE fluorescent tagged biomarkers provided by reagent vendors to identify cell populations MORE lasers and detectors provided by instrument manufacturers to measure these fluorescent biomarkers CYTEK TRANSCEND THE CONVENTIONAL CO#7We Provide an End-to-End Platform of FSP Solutions Instruments Aurora CYTEK M Application & Service Conc Northern Lights Cell Sorter Reagents & Kits tette da V FULL SPECTRUM 5-LASER CYTOMETRY AT A GLANCE Pues of de Vale --- PEET im - m CYTEK A CYTEK Software CYTEK TRANSCEND THE CONVENTIONAL CYTEK N#8Strategy to Drive Innovation in the Cell Analysis Market Instruments Software W Reagents KI Services Becoming a Comprehensive Solutions Provider and Driving Innovation in Cell Analysis Continue facilitating technical innovation in cell analysis Broad application development across life sciences, and healthcare more broadly: - Discovery, translational and clinical research Clinical diagnostics CYTEK TRANSCEND THE CONVENTIONAL ∞#9Our FSP Platform Allows Us to Address the Broader Cell Analysis Market Agilent BIO RAD Technologies FLUIDIGM BECKMAN $3.0B Cell ID COULTER Miltenyi Biotec BD Marine Biology Thermo Fisher $8B Initial TAM (Cell Analysis Market in 2019 Addressable by Flow Cytometry) SCIENTIFIC $1.9B Cell Proliferation SONY $1.6B Cell Counting & QC $1.0B Single Cell Analysis $2.4B Cell Viability $8B Additional TAM (Cell Analysis Market in 2019 Not Currently Addressable by Flow Cytometry) $23B Long-Term TAM (Total Cell Analysis Market in 2024) Water Supply Contamination $2.4B Cell Signaling $1.3B Cell Interaction Alternative Biofuels $1.3B Target ID CYTEK TRANSCEND THE CONVENTIONAL $1.1B Cell Structure O#10Advancing Cell Analysis with Our Unique FSP Technology Cytek's FSP Technology Conventional 80 80 70 80 50 20 10 ^ 300 Ignored PE Channel Compensated 7:00 FITC = Green!... or emission from 515-545 (530/30 BP) PE cFluor YG584 UV Channels Violet Channels Blue Channels Y/G Channels Red Channels ENTIRE emission spectrum is captured across the different module & stitched together to create a spectral signature that combines emission information of fluorochrome excited by all onboard lasers CD8 APC 13 APC Alexa Fluor 647 0 4.0M- 3.0M- 2.OM- 1.0M- NK cells NK cells Aurora Full Spectrum 10¹ 10² CD56 Alexa 647 Non T cells 010 APC 10⁰ Unmixing T cells 104 CD3 FITC CD8 APC 10. 10³- Alexa Fluor 647 -10- 10⁰ NK T cells NK T cells -10* 0 10¹ 10³ CD56 Alexa 647 Our FSP platform was purpose- built to advance the next generation of cell analysis by delivering deep insights, high throughputs and ease of use FSP technology enables high sensitivity and high throughput without compromising data quality Allows use of many dyes simultaneously with optimal resolution, which is not possible with conventional cytometers FSP is able to extract autofluorescence to enhance resolution CYTEK TRANSCEND THE CONVENTIONAL 10#11C Our FSP Technology is Powered by Innovative Designs APD DETECTOR MODULE DETALL WW TE EXTR CE ECR 2 CE EGICE I DE ESTRA CYTEK AURORA U DETECTURN VIRTORS Maximize Resolution & Accuracy LASERS A WAPO DETECTOR MODULE VYLET APD DETECTOR MODULE FLOW CELL SUE APO DETECTOR MODULE SAMPLE FIBER OPTICS RED AND DETECTOR MODULE YİGRIN APD DEFECIOR MODULE Optimized Signal-to-Noise Ratio ULTRAVIOLET B VIOLET CHANNELSI C&CHANNELS) KLANT BLUC 116 CHANNELS YELLOW-GREEK RED SPECTROFLO DISPLAY CHANNELS) 18 CHANNELS) High Resolution MANCES562 FRAMEA D quantum efficiency (%) 100 10 0.1 200 PMT APD photodiode 400 600 800 wavelength (nm) Valuable Insights 1000 1200 A The fluorescence spectrum from each laser source is collected from multiple laser excitation B The fluorescence from each laser source is collected by each corresponding detector array module C Use of APD detectors maximizes sensitivity and enables broad wavelength responses D The combination of our patented optical design with APD detectors yields high- resolution data at an optimized signal-to-noise ratio CYTEK TRANSCEND THE CONVENTIONAL 11#12Benefits of Our FSP Platform vik x Ultra-sensitive Resolves the most challenging cell populations Deep, high-integrity content Highly complex assays through access to 40 different colors in a single tube Flexible and compatible Single configuration across a wide range of reagents and applications Efficient and compact Saves time and money while maintaining industry-leading performance Integrated and intuitive Fully integrated workflows with end-to-end solutions CYTEK TRANSCEND THE CONVENTIONAL 12#13Cytek's Core Instruments: Aurora and Northern Lights >40 Colors from 3-5 Lasers CYTEK™ AURORA Aurora Biopharma, CROS, Large Academic Labs High-Throughput High-End Market x Flexible & Intuitive >24 Colors from 1-3 Lasers Northern Lights CYTEK NL-3000 viki Ultra-Sensitive Individual Researchers & Clinical Labs هههه Entry-Level Market Valuable Insights 13#14Newly Launched: Aurora Cell Sorter Overview CYTEK Aurora Cell Sorter Shipped June 2021 First highly flexible, intuitive and ultra-sensitive cell sorter that leverages the detection and sensitivity capabilities of our FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers Unique ■ Accommodates the same number of parameters with the same sensitivity as the Aurora system Able to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers Ability to easily transfer panels from Aurora, as well as other or conventional instruments, to sorter Easy integration for downstream analysis (e.g., genomics and proteomics) Differentiated Can analyze and sort using higher complexity panels, in addition to ability to isolate living cell populations Sustainable Higher complexity spectral panels cannot be run on a conventional sorter Cytek sorter can also be used to sort panels from conventional analyzers CYTEK TRANSCEND THE CONVENTIONAL 14#15Cytek' FSP Platform versus Other Technologies Conventional Flow Cytometry Biomarkers / Parameters (>40 biomarkers)¹ Sensitivity (nanoparticle detection) Throughput (>30K cell/second) Footprint (<150K cm³) Sorting Capability Cost Performance² 1. Based on peer-reviewed publications 2. CYTEK TRANSCEND THE CONVENTIONAL X X Spectral Flow Cytometry X X X X X Cost-to-Performance reflects performance based on accessible biomarkers, sensitivity, throughput and sorting capabilities, relative to costs associated with instruments, consumables, time, labor and ability to upgrade over time Mass Cytometry X X X X X CYTEK TRANSCEND THE CONVENTIONAL 15#16% NORMALIZED EMISSION Our FSP Technology Provides a Significant Reagents Opportunity Laser Violet Violet Violet Violet Violet Blue Blue Blue Blue Blue Blue Blue Blue Blue Blue Blue Yellow Green Red Red Red Red Red Red Violet Red Cytek developed a set of spectral unique dyes based on full spectrum cytometry About 20 cFluor dyes are identified and several have been commercialized Additionally, we market a cFluor immunoprofiling kit with 14 colors Fluorescence spectrum of Cytek cFluor dyes can be stored in the instruments for ease of use and bundling with instruments 100 90- 80 - 70- 60- 50- 40- 30- 20- 10- 0 UV1 UV2 UV3 UV4 UVS UV6 UVI UV8 UV9 UV10 UV11 UV12 UV13 UV14 UV15 UV16 2 V15 EMISSION CHANNEL B11 B12 B13 B14 YG1 YG2 YG3 YG4 YG5 YG6 YG7 YG8 YG9 YG10 cFluor cFluor V420 cFluor V450 cFluor V500 cFluor V570 cFluor V620 cFluor B518 cFluor B532 cFluor B548 cFluor BYG575 cFluor BYG610 cFluor BYG628 cFluor BYG666 cFluor BYG676 cFluor BYG680 cFluor BYG710 cFluor BYG781 cFluor YG584 cFluor R659 cFluor R667 cFluor R685 cFluor R720 cFluor R780 cFluor R810 ViaViolet ViaRed CYTEK TRANSCEND THE CONVENTIONAL 16#17Reagents & Kits Portfolio CYTEK Reagents & Kits Commercially Launched October 2020 Our reagents are fluorochrome conjugated antibodies used to identify cells of interest Simplifies the workflow from sample preparation to data analysis Our 14-color cFluor immunoprofiling kit and 40-color optimized multicolor immunofluorescence panel provide users with ready-to-use protocols and antibodies Class 1 single-color reagents currently sold in China with clinical studies underway for 6-color TNBK reagents for potential Class 3 registration CYTEK TRANSCEND THE CONVENTIONAL 17#18Web-Based Tool Developed to Help Customers to Advance HD Cell Analysis Fluorochrome Selection Guidelines Cytek® Aurora Fluorochrome Selection Guidelines 5 Laser 16UV-16V-14B-10YG-8R Violet Laser Excitable Dyes with Unique Signatures BV421 Alexa Fluor 405, Super Bright 436, Zembla Violet Fluor 450, Viel, Pacific Blue, Live/Dead Violet BV480 CYTEK TRANSCEND THE CONVENTIONAL Fluor 506 BV510, VieGreen, Zombie Aqua, Live/Dead Aqua BV570 Pacific Orange, Live/Dead Yellow SuperBright 600, BV605 WW Zombie Yellow Quot505 BV650, SuperBright 645 Qdot655 Qdat708 Odot 800 Grid: Show Configuration 5L 16U-16148-10G-BR Cytek Full Spectrum Viewer Spectrum Viewer View and overlay full spectrum signatures Fluorochrome 7AAD Search by nama Search by peak channe Alexa Fluor 350 Alexa Fluor 488 Alexa Fluora 540 Alexa Fluor 555 EMISSION CHANNEL Alexa Fluor 594 Alexa Fluor 650 Aleva Fluer 680 Export SpectraSimilarity Matrix Tags 36 Tags Added Double click Flyerochromes to add Alexa Fluor 532 Alexa Fluor 647 Alexa Fluor 200 APC-Fire 750 88515 BUV395 BUV490 BUVS63 BUV615 Clear All Ⓡ O 0 O 0 O €3 Ⓡ For full spectrum viewer functionality, please use Google Chrome Other browsers do not support all features built into the viewer and using them will result in display issues and possibly other loss of functionality Don't see a fluorochrome you use in the list above, or have other suggestions? Let us know: SA Unmix Experiment Select Controls Similarity and Complexity Indices Identify Positive/Negative Populations QC Controls Select a Control to View. Available Controls L EX Spectral Profile Similarity Matrix Hide Similarity Index Super Bright 436 Super Bright 600 FITC BB700 PerCP-Cy5.5 PE PE-Cy7 APC APC-Cy7 Complexity Index: 10.9 PerCP-Cy5.5 1 0.12 0.01 0 0.01 0.01 0 0 0 0.01 0.02 0.12 1 0.02 0.17 0.14 0.25 0.02 0.08 0.01 0.01 0.14 0 0.98 2 0.03 0 0.17 0 0 0 0,17 0.03 1 0.98 0.1 0.27 0.34 0.15 S 0.01 0.25 0.17 0.1 0.06 0 1 0.06 0.27 0.3 0.13 0 0.02 0.01 1 0.02 0 0.27 0.27 0.021 0.03 0.19 0 0.08 0 0.34 0.3 0.01 0.03 1 0.18 0 0.01 0 0.15 0.13 0 0.19 0.18 1 Compare and evaluate fluorochrome combinations 0 SpectroFlo Experiment Builder Fluorescent Tags Name Groups My 14 Color Aurora Experiment. Description (optional) 5L 16UV-16V-148-10YG- Experiment Builder Markers Search by name Fluorochrome 7AAD Alexa Fluor 350 Alexa Fluor 405 Alexa Fluor 488 Alexa Fluor 532 Alexa Fluor 546 Alexa Fluor 555 Alexa Fluor 561 Alexa Fluor 568. Alexa Fluor 594 Alexa Fluor 647 Alexa Fluor 660 Alexa Fluor 680 Alexa Fluor 700 14 Tags Added Selection cFluor V420 cFluor V450 cFluor V547 cFluor B515 cFluor BYG575 cFluor BYG667 cFluor 8690 cFluor BYG710 cFluor BYG781 cFluor R659 cFluor R668 cFluor R720 cFluor R780 cFluor RB40 Import CYTEK TRANSCEND THE CONVENTIONAL Reset Experiment Create SpectroFlo experiment templates • Clear All X Ⓡ 18 Ⓡ 0 0 Next →#19End-to-End FSP Workflow 01 Animal or Human Samples Whole Blood PBMCs Tissue(s) Sample Collection 02 Tubes Sample Cell Plate 03 Aurora Spectral Signature Cermi SPECTROFLO DISPLAY Sample Preparation Full Spectrum Profiling & Labeling 04 Dot Plots Sample Acquisition Live Unmixing 05 Dimensionality Reduction Standardized, fully-integrated FSP workflow solution, incorporating instruments, reagents, software and services to provide a seamless end-to-end experience, increasing usage of high-dimensional cell analysis techniques by more end-users and accelerating market adoption Advanced Analysis CYTEK TRANSCEND THE CONVENTIONAL 19#20Development Strategy for Driving New Applications via Reagents Work with industry partners / KOLs to potentially co- develop new fluorophores and antibody conjugates with unique spectral characteristics Evaluate unique fluorophore prototypes to consider future development of additional products or processes + + Leukemia & Lymphoma Diagnosis Collaborations with Clinical Laboratories to design and study potential clinical diagnostics Identify and develop a larger range of conjugated antibodies that can be combined across each laser to increase the number of colors that can be effectively used together, with optimal resolution, in laboratory research and clinical diagnostics Minimal Residual Disease Monitoring CYTEK TRANSCEND THE CONVENTIONAL 20#21Comparable performance between 3-tube assays with CFC and 1-tube assays with NL-CLC New diagnosis method is discovered when multiple tubes are combined Legend: Live Single Cells Myeloid Cells Conventional 3-Tube Assay Full Spectrum NL-CLC 1-Tube Assay CD33 10º 10⁰ 10⁰ CD 15 10' 10° 10° 10" CD 13 Monocytes 10⁰ 10" 10- 10¹- 10⁰ 10⁰ 10- 10 CD34 10⁰ 10" 10⁰ 10' Mature Lymphocytes 10" 10" HLA-DR 10²- 10" 10⁰- 10³ - 10⁰ 10%. 10. 10' CD15 10° CD34+ Blast Cells CD 117 10²- 03 10- 10%- 10- 10¹. 10⁰ 10' 10° CD38 10⁰ CD34 10⁰- 10⁰. 10%- 10 10°- 10% 10. CD33 10* CYTEK TRANSCEND THE CONVENTIONAL 10⁰ 10° 10° 10° 21#22First 40-color Optimized Multicolor Immunofluorescence Panel ISAC CYTOMETRY Fasa De C BeFromC OMIP-069: Forty-Color Full Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human Peripheral Blood Lily M. Park,' Joanne Lannigan, Maria C. Jaimes" MS 400 Fowy Sport LL Alm Vega 32058 Brow Accepted July Acil Sungamation may In the IMEL "Mamta E.dai Devement Cyrt FC FC 00:0 Inc., 45100 Landing Parkway, T darmot Cylik Bie way. 2000 Ca kod by Wiley P LUC SA This artic CC AND Li, which pernix use and dir A prádel 14 any ja malwark properly, and a ISAC PA-120 PURPOSE AND APPROPRIATE SAMPLE TYPES This 4-o camery-based panel w developed for in-depth i OMIP M Viimot of the Sample en belated, especially in altri material when tiple type af ingannequined from a single sample or inpoint Maximizing the on that can be used from de sarpel mon in-depth duracterization of the impatto add the fple ability. The pred pred hem de CD4 Tel CDI call, alory Todd, y T celle, NT Lock, 5 celle, NC cells, monac and details Fit mich gecike all tyge, the past includes refer by changes of action and direk well as chemokine coptan Mower, the combination of driple makers in one tight ked to the very of mis phenotype and their in outain di Ct nane, this panel was desigrand to include only rice carot the need for Esstion and permocions The pand can be for s characng the reasa pens in the of infoarte las imme amtaring cancer patients patiens se inmuno chemothes, and discovery of anique and table bomarkers. Derent from al from all previa OMIPS, this past was developed using a full spectrum four contra technology that had the affectree of lacrescent markens in a single pand. The pand Buruz paphand bad ma Key torms Aussa; haud immunophenotyping full spectra high-dinara OM was developed wing sysposurved (PBMC) foky adsko Table 1 Although we have not reste ganciones PRMO wa had, it is stated that the palad been the with furter op 20 BI c PRMC BACKGROUND The ad ukrad the much akher post matherapy and and pathways of va posso cascar, wat das que me and wish will Grecandination of inmate subpag- der profing of the imate were informed decisions garding the Haration of li bons and the development of new thematic appesada. (1-4 Ung the complexity of the human immune impone requins the ability to periam High-through, in-depth analys there cell and pl Rew yory has sought to address the need by aouing the character of single-cell en exssion, through the bending of Dundreds umap_2 10 13 1 Naive CD41 2 Central Memory CD4 19 3 Early Effector CD4 4 Early Like Effector CD41 5 Early Effector CD4 PD-11 6 CD4 CD57 7 CD4 CD127 CD25" CD45RA 8 CD4 CD127 CD25 CD45RA CD395 9 CD4 CD127 CD25 CD45RA CD39 28 29 umap_1 26 33 34 10 Naive CD8- 11 Central Memory CD8 12 Early Effector CDB 13 Intermediate Effector CD8 14 CD8 CD4SRA CCR7 15 CD8 CD45RA" CCR7 16 CD45RA Terminal Effector CD8+ 17 CCR7 CD45RA TCR 18 CCR7 CD45RA TCR 35 Donor 3444 19 CD2 CD8 NKT-like 20 CD2 CD8 NKT-like 21 CD4 CDB 22 CD4 CD6- 23 ILCs 24 Early NK 25 Mature NK 26 CD159 NK 27 Mature NK CD159c Donor 3458 umap_1 28 IgD CD27 B cells 29 IgD CD27 8 cells 30 igD Memory 31 lgG B cells 32 PDCs 33 CD1C DCs 34 CD1c- CD141 DCs CD45 CD123 HLA-DR Besophils Classical Monocytes Donor 4559 Donor 5036 Intermediate Monocytes Non-classical Monocytes Number of colors/sotopes 50 40 30 10 0 First publication to go beyond 28-color fluorescence flow cytometry, exceeding OMIP panels published using mass cytometry 40-color panel covering almost the entire cellular composition of the human peripheral immune system with a single tube Higher throughput, robust population resolution and lower cost n = 2 Mass cytometry Full spectrum flow cytometry 2010 OLL 1 11 5 5 6 2011 2012 2013 2014 2015 5 2016 Publication year ↓ OC 5 10 2017 2018 CYTEK TRANSCEND THE CONVENTIONAL CYTEK TRANSCEND THE CONVENTIONAL xa T 12 8 2019 2020 22#23Validation as Publications have Increased Significantly Over Time Cells 3 Q3 '18 Cancer Research The Foundational Cancer Journal Driving Transformative Science www.AACRma.arg 6 Q4 '18 April 1, 2018 Volume 24 AAGR A for Cancer Research 9 Q1 '19 JCI INSIGHT December 2018 tatume? 24 Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy 11 insight.jc.org Q2 '19 17 Q3 '19 The Journal of Immunology 24 Q4 '19 nature Advances INSIDE GREEN FLUORESCENT PROTEIN The vibration that powers the classic gene expression marker PANDEMIC FL In the lab with HIN1 DUAL ROLE FOR UNIVER Towards a new social contract THE ORIGINS OF SPEED FOXP2 and the chimp-human divide 44 Q1 '20 67 NATUREJOBS Distant learning Q2 '20 NAAAS 103 Q3 '20 8 JANUARY 2021 158 Q4 '20 211 Q1 '21 270 Q2 '21 CYTEK TRANSCEND THE CONVENTIONAL 23#24Growing Market Needs Require Advanced Cell Analysis 8 Flow cytometry used in clinical settings and provide new possibilities for novel drug development The Rise of Immuno-Oncology 8 Customers demand increased access to high parameter flow cytometry at both the high-end and low-end entry points Demands of Flow Cytometry Customers are Increasing Market is characterized by large, legacy players and a dearth of innovation, thus there is a large appetite for novel solutions Opportunity to Innovate a Market Suffering from Inertia The diagnostics sector has enjoyed a period of significant innovation, particularly within the fields of genomics and proteomics Clinical Diagnostics are Changing Drive adoption and application development of Cytek's FSP platform 24#25Cytek's Value Proposition to the Clinical Market CYTEK NL-3000 N NL-CLC ■ ■ Benefits Allows for more informative antibodies in one tube Minimizes use of redundant reagents Optimizes use of smaller amounts of patient specimen Identifies small populations of abnormal cells Improves overall laboratory efficiency Lowers costs ■ ■ ■ ■ Performs high-level multi-parameter flow cytometry immunophenotyping on small sample amounts ■ Accurately detects, diagnoses and monitors immune cell disorders with very low levels of key biomarkers Becoming a Solutions Provider for the Clinical Market diketiki Automated Sample Preparation Customized Workflow Solutions Automated Analysis Error Reduction CYTEK TRANSCEND THE CONVENTIONAL 25#26The Power of "AND" Flow cytometry is often used with downstream or companion technologies Flow Cytometry Sorting Flow Cytometry Analysis Cytek cFluor™ Reagent Kits Immuno-oncology Immunotherapy ● ● CYTEK™ NL-CLC ● Infectious disease Minimal residual disease m Next Gen Sequencing 10x illumina GENOMICS High Content Imaging FINAN Molecular Biology MEN||||||||| IN T ADVANCED SCIENCE Full Paper Open Access Ⓒ+ The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1 Hui Li, Xinwei Kuang, Long Liang. Youqiong Ye, YongChang Zhang, Jialu Li, Fangyu Ma. Juan Tao, Guang Lei. Shuang Zhao. Juan Su. Nong Yang. Cong Peng. Xiaowei Xu ... See all authors ✓ First published: 27 November 2020 | https://doi.org/10.1002/advs.202001596 ADVANCED SCIENCE NEWS www.van.cecs ciencenews.com B E J Ugu204) Dou27431 RURAL BLACK sland in den WERD po langs LIB D LAR Sun) m pai 400 EGS A.376 IDO 2.5 Relative agre Open Access 201 www.ciscience.com A375 ADVANCED SCIENCE Sk-mel 20 UCK Suniti Sub-1.5 Sud- 42LCON $2.mel.31 FN-Gng mil ENT -- CYTEK TRANSCEND THE CONVENTIONAL 26#27Cytek is Transforming into a Full Solutions Provider Thought Leadership 1. 2. Establish 3. Place instruments at top research universities and corporations across US, Europe and Asia 000 850+ Instrument placements Drive Cutting- Edge Applications Focus on high value areas of scientific research and discovery 270+ Publications Position the Platform for Broad Use H™- Drive placements at pharma, biotech and CRO customers 125+ Biopharma Customers Translate into the Clinical Setting Develop applications for clinical setting using our FSP technology $23Bn Broader Cell Analysis TAM¹ 2024 market projection estimate We define Adjusted EBITDA as net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for (benefit from) income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses. Adj. EBITDA Margin is on a percentage of revenue basis. Represents longer term financial objectives of the Company and does not constitute estimates of the Company's future performance, financial, or otherwise. There is no assurance that the Company will ever achieve any of these objectives. See Special Note Regarding Forward-Looking Statements Transformation into Solutions Provider End-to-end solutions provider, including instruments, reagents, software and services Strong and Scaling Adj. EBITDA2,3 CYTEK TRANSCEND THE CONVENTIONAL 27#281. 2. Global Scale and Reach with Diversified Revenue Mix Since launch of Aurora Series in 2017¹... 620+ Customers 390+ Employees 125+ Biopharma Companies 25+ Countries WW Applications, Service & Sales % Revenue by Industry² 56% 44% As of Initial Public Offering, July 22nd, 2021 As of June 30, 2021 Fremont (Headquarters) Academic and Government-Owned Institutions ■ Pharmaceutical and Biotechnology Companies, Distributors and CROS Bethesda Amsterdam % Revenue by Region² USA 57% EMEA 32% Wuxi Shanghai APAC 11% Tokyo CYTEK TRANSCEND THE CONVENTIONAL 28#291. Strong and Growing Base of Instrument Placements¹ 303 Q4'19A 376 Q1'20A 447 Q2'20A CAGR (Q4'19 - Q2'21) 19% 548 Q3'20A Cumulative number of instruments (Aurora, Cell Sorter, Northern Lights and Athena) sold and delivered to our customers as of the dates presented 657 Q4'20A 751 Q1'21A 855 Q2'21A CYTEK TRANSCEND THE CONVENTIONAL 29#30Historical Revenue and Gross Margin ($ in millions) Quarterly Revenue ($)¹ / Gross Margin (%) $18.0 $1.9 47% $16.1 $19.1 $1.7 43% $17.4 $25.1 $1.9 Service Revenue 62% $23.2 $30.6 $2.0 64% Note: Fiscal year ended December 31 and second quarter ended June 30 1. Product revenue includes reagents $28.6 Product Revenue $24.3 $1.6 60% $22.7 $30.4 $1.7 Q1'20A Q2'20A Q3'20A Q4'20A Q1'21A Q2'21A 65% $28.7 Gross Margin Annual Revenue ($)1/ Gross Margin (%) $57.9 $7.7 50% $50.2 FY2019A Service Revenue YoY growth 60% Product Revenue $92.8 $7.6 56% $85.2 FY2020A Gross Margin CYTEK TRANSCEND THE CONVENTIONAL 30#31Key Improvement Drivers ■ Gross Margin Shift in product mix with higher margin reagents becoming a greater share of total revenue Benefit from economies of scale as Company grows Leverage global manufacturing capabilities S&M ▪ Increased publications improve brand recognition and lowers customer acquisition costs ▪ Improved variable costs to retain and service customers at scale ■ ■ R&D Lower cost to develop new products by leveraging existing FSP platform Talent diversification in other lower cost locations Lower fixed costs to operate at scale G&A Improved operating costs through system automation ▪ Talent diversification in other lower cost locations CYTEK TRANSCEND THE CONVENTIONAL 31#32Advancing the Next Generation of Cell Analysis Tools High-Resolution, High-Content and High-Sensitivity Entire Spectrum of a Fluorescent Signal Integrated Platform Over 270 Peer-Reviewed Articles Global Scale and Reach Flexible, Easy-to-Use and Reconfigurable Lasers Differentiated, Cost-Effective and High Performance